These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7562930

  • 1. Pseudodipeptide inhibitors of protein farnesyltransferase.
    deSolms SJ, Deana AA, Giuliani EA, Graham SL, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH.
    J Med Chem; 1995 Sep 29; 38(20):3967-71. PubMed ID: 7562930
    [Abstract] [Full Text] [Related]

  • 2. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Jan 13; 270(2):660-4. PubMed ID: 7822292
    [Abstract] [Full Text] [Related]

  • 3. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC, Qian Y, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Nov 10; 270(45):26770-3. PubMed ID: 7592913
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y, Vogt A, Sebti SM, Hamilton AD.
    J Med Chem; 1996 Jan 05; 39(1):217-23. PubMed ID: 8568811
    [Abstract] [Full Text] [Related]

  • 5. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD.
    Bioorg Med Chem; 1999 Dec 05; 7(12):3011-24. PubMed ID: 10658608
    [Abstract] [Full Text] [Related]

  • 6. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.
    Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD.
    J Med Chem; 1999 Apr 22; 42(8):1333-40. PubMed ID: 10212118
    [Abstract] [Full Text] [Related]

  • 7. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ, Johnson RL, Weinbaum CA, Sakabe K, Chen Z, Casey PJ, Cox AD.
    J Biol Chem; 2003 Oct 24; 278(43):41718-27. PubMed ID: 12882980
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors.
    Reuveni H, Gitler A, Poradosu E, Gilon C, Levitzki A.
    Bioorg Med Chem; 1997 Jan 24; 5(1):85-92. PubMed ID: 9043660
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of protein farnesyltransferase as novel anticancer agents.
    Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD.
    Curr Top Med Chem; 2002 Mar 24; 2(3):303-23. PubMed ID: 11944822
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 24; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 11. Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus.
    Huang CF, Chen CH, Chuang NN.
    J Exp Zool; 2001 Jun 01; 289(7):441-8. PubMed ID: 11351331
    [Abstract] [Full Text] [Related]

  • 12. Farnesylation and proteolysis are sequential, but distinct steps in the CaaX box modification pathway.
    Farh L, Mitchell DA, Deschenes RJ.
    Arch Biochem Biophys; 1995 Apr 01; 318(1):113-21. PubMed ID: 7726551
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.
    Lerner EC, Hamilton AD, Sebti SM.
    Anticancer Drug Des; 1997 Jun 01; 12(4):229-38. PubMed ID: 9199657
    [Abstract] [Full Text] [Related]

  • 14. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
    Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F.
    J Cell Biochem Suppl; 1997 Jun 01; 27():12-9. PubMed ID: 9591188
    [Abstract] [Full Text] [Related]

  • 15. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB, Kohl NE, Koblan KS, Omer CA, Sepp-Lorenzino L, Rosen N, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A.
    Breast Cancer Res Treat; 1996 Jun 01; 38(1):75-83. PubMed ID: 8825125
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.
    McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD.
    Biochem Biophys Res Commun; 1995 Sep 05; 214(1):295-303. PubMed ID: 7669049
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and evaluation of a novel series of farnesyl protein transferase inhibitors as non-peptidic CAAX tetrapeptide analogues.
    Perez M, Maraval C, Dumond S, Lamothe M, Schambel P, Etiévant C, Hill B.
    Bioorg Med Chem Lett; 2003 Apr 17; 13(8):1455-8. PubMed ID: 12668011
    [Abstract] [Full Text] [Related]

  • 19. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM, Yan N, Cox AD, Bustelo X, Graham SM, Lynch MJ, Weinmann R, Seizinger BR, Der CJ, Barbacid M.
    Oncogene; 1995 May 18; 10(10):1905-13. PubMed ID: 7761092
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.